Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A gynecologic oncology group study Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Endometrial Neoplasms

abstract

  • Bevacizumab is well tolerated and active based on PFS at 6 months in recurrent or persistent EMC and warrants further investigation.

publication date

  • June 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3107744

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.6397

PubMed ID

  • 21537039

Additional Document Info

start page

  • 2259

end page

  • 65

volume

  • 29

number

  • 16